Linda M. Smith Resar, MD

Primary Academic Title

Professor of Medicine

Background

Centers and Institutes

Cell Engineering, Institute for

Additional Academic Titles

Professor of Pathology, Professor of Oncology

Research Interests

Basic research focus is hematologic malignancy and molecular mechanisms that lead to cancer, Clinical research interests include sickle cell anemia.

Lab Website

Linda Smith-Resar Lab - Lab Website

• The Linda Smith-Resar Lab primarily investigates hematologic malignancy and molecular mechanisms that lead to cancer as well as sickle cell anemia. Recent studies suggest that education is an important and effective component of a patient blood management program and that computerized provider order entry algorithms may serve to maintain compliance with evidence-based transfusion guidelines. Another recent study indicated that colonic epithelial cells undergo metabolic reprogramming during their evolution to colorectal cancer, and the distinct metabolites could serve as diagnostic tools or potential targets in therapy or primary prevention.

Research Summary

Dr. Resar's studies molecular mechanisms leading to cancer, blood diseases, sickle cell anemia, hemophilia and other coagulopathies. Her research focuses on the HMG-I/Y gene family, which is widely overexpressed and functions as oncogenes in human cancers. Her laboratory recently developed transgenic mice overexpressing HMG-I; all mice develop aggressive lymphoid malignancy similar to leukemia and lymphoma in humans. Her studies also demonstrate that this gene is overexpressed in human lymphoid and other malignancies. Translational studies are underway to determine if overexpression of HMG-I is a marker for more aggressive human cancers. Resar's long-term goal is to develop more rational therapies that interfere with HMG-I/Y function in neoplastic transformation.

PubMed

http://www.ncbi.nlm.nih.gov/pubmed/?term=Resar+LM

Selected Publications

• Resar, L.M. The high mobility group A1 gene: transforming inflammatory signals into cancer? Cancer Res. 2010 Jan 15;70(2):436-439

• Di Cello, F.; Hillion, J.; Hristov, A.; Wood, L.J.; Mukherjee, M.; Schuldenfrei, A.; Kowalski, J.; Bhattacharya, R.; Ashfaq, R.; Resar, L.M. HMGA2 participates in transformation in human lung cancer. Mol Cancer Res. 2008 May;6(5):743-750

• Di Cello, F.; Hillion, J.; Kowalski, J.; Ronnett, B.M.; Aderinto, A.; Huso, D.L.; Resar, L.M. Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts. Mol Cancer Ther. 2008 Jul;7(7):2090-2095

• Hillion, J.; Dhara, S.; Sumter, T.F.; Mukherjee, M.; Di Cello, F.; Belton, A.; Turkson, J.; Jaganathan, S.; Cheng, L.; Ye, Z.; Jove, R.; Aplan, P.; Lin, Y.W.; Wertzler, K.; Reeves, R.; Elbahlouh, O.; Kowalski, J.; Bhattacharya, R.; Resar, L.M. The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an Achilles heel for hematopoietic malignancies Cancer Res. 2008 Dec 15;68(24):10121-10127

• Hillion, J.; Wood, L.J.; Mukherjee, M.; Bhattacharya, R.; Di Cello, F.; Kowalski, J.; Elbahloul, O.; Segal, J.; Poirier, J.; Rudin, C.M.; Dhara, S.; Belton, A.; Joseph, B.; Zucker, S.; Resar, L.M. Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer. Mol Cancer Res. 2009 Nov;7(11):1803-1812

• Hines, P.; Dover, G.J.; Resar, L.M. Pulsed-dosing with oral sodium phenylbutyrate increases hemoglobin F in a patient with sickle cell anemia. Pediatr Blood Cancer. 2008 Feb;50(2):357-359

• Hristov, A.C.; Cope, L.; Di Cello, F.; Reyes, M.D.; Singh, M.; Hillion, J.A.; Belton, A.; Joseph, B.; Schuldenfrei, A.; Iacobuzio-Donahue, C.A.; Maitra, A.; Resar, L.M. HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Mod Pathol. 2010 Jan;23(1):98-104

• Hristov, A.C.; Cope, L.; Reyes, M.D.; Singh, M.; Iacobuzio-Donahue, C.; Maitra, A.; Resar, L.M. HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol. 2009 Jan;22(1):43-49

• Karp, J.E.; Smith, B.D.; Resar, L.S.; Greer, J.M.; Blackford, A.; Zhao, M.; Moton-Nelson, D.; Alino, K.; Levis, M.J.; Gore, S.D.; Joseph, B.; Carraway, H.; McDevitt, M.A.; Bagain, L.; Mackey, K.; Briel, J.; Doyle, L.A.; Wright, J.J.; Rudek, M.A. Phase I and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood. 2011 Jan 14;Epub 1/18/11

• Mazaheri, P.; Nadkarni, G.; Lowe, E.; Hines, P.; Vuica, M.; Griffin, M.; Resar, L.M. Ghosal hematodiaphyseal dysplasia: a rare cause of a myelophthisic anemia. Pediatr Blood Cancer. 2010 Dec 1;55(6):1187-1190

• Savage, W.J.; DeRusso, P.A.; Resar, L.M.; Chen, A.R.; Higman, M.A.; Loeb, D.M.; Jones, R.J.; Brodsky, R.A. Treatment of hepatitis-associated aplastic anemia with high-dose cyclophosphamide. Pediatr Blood Cancer. 2007 Dec;49(7):947-951

• Tesfaye, A.; Di Cello, F.; Hillion, J.; Ronnett, B.M.; Elbahloul, O.; Ashfaq, R.; Dhara, S.; Prochownik, E.; Tworkoski, K.; Reeves, R.; Roden, R.; Ellenson, L.H.; Huso, D.L.; Resar, L.M. The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis. Cancer Res. 2007 May 1;67(9):3998-4004